- Title: Subtitle
- First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors
- Creators
- Jonathan R. Strosberg - Moffitt Cancer CenterEdward M. Wolin - The Bronx DefendersBeth A. Chasen - The University of Texas MD Anderson Cancer CenterMatthew H. Kulke - Boston University/Boston Medical Center, Boston, MADavid L Bushnell - University of IowaMartyn E. Caplin - The Royal Free HospitalRichard P. Baum - Zentralklinik Bad BerkaTimothy J. Hobday - Mayo ClinicAndrew Eugene Hendifar - Cedars-Sinai Medical CenterMaribel Lopera Sierra - Advanced Accelerator Applications, New York, NYKjell E. Oberg - Uppsala University HospitalPhilippe B. Ruszniewski - Beaujon HospitalEric Krenning - Erasmus MC
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.4099-4099
- DOI
- 10.1200/JCO.2018.36.15_suppl.4099
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Radiology
- Record Identifier
- 9984320089102771
Abstract
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors
Journal of clinical oncology, Vol.36(15_suppl), pp.4099-4099
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.4099
Details
Metrics
8 Record Views